Richard T Maziarz
Affiliation: Oregon Health and Science University
- Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assayYanping Zhong
Department of Pathology, Oregon Heath and Science University, Portland, Oregon 97201 3098, USA
Cytometry B Clin Cytom 72:189-95. 2007..It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals...
- Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?"Richard T Maziarz
Mayo Clin Proc 78:941-3. 2003
- Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspectiveRichard T Maziarz
Bone Marrow Transplantation Program Leukemia Center, Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Bone Marrow Transplant 32:459-69. 2003..Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient...
- Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantationBrandon Hayes-Lattin
Adult Bone Marrow Transplant Program, Division of Hematology and Medical Oncology, Oregon Health and Science University, The OHSU Cancer Institute, Portland, Oregon 97239, USA
Am J Hematol 75:142-5. 2004..Characteristics of parvovirus B19 infection and the immunosuppressed state after allogeneic stem cell transplantation are reviewed...
- Optimal benefits for hematopoietic stem cell transplantation: a consensus opinionRichard T Maziarz
Adult Blood and Marrow Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon Electronic address
Biol Blood Marrow Transplant 20:1671-6. 2014..The recommendation was to encourage adoption of these benefits at a national level by payers, benefit brokers/consultants, and sales teams. ..
- Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trialRichard T Maziarz
Knight Cancer Institute, Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon Electronic address
Biol Blood Marrow Transplant 21:720-8. 2015..MAPC contribution to blood chimerism was negligible. These phase I data support the safety of stromal stem cell therapy and suggest that MAPC should be tested prospectively as a novel therapeutic option for GVHD prophylaxis after HCT...
- Adult adherent stromal cells in the management of graft-versus-host diseaseLaura F Newell
Oregon Health and Science University, OHSU Knight Cancer Institute, Center for Hematologic Malignancies, Portland, OR 97239, USA
Expert Opin Biol Ther 14:231-46. 2014..Subset analyses demonstrated efficacy in selected patient populations, contributing to recent approvals of MSC for pediatric patients in Canada and New Zealand...
- Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cellsRichard T Maziarz
Center for Hematologic Malignancies and Adult Blood and MarrowTransplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Biol Blood Marrow Transplant 19:670-5. 2013..These findings may provide insight into the optimal use of plerixafor in all patients undergoing stem cell mobilization...
- Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?Richard T Maziarz
Bone Marrow Transplantation Program, Oregon Health and Science University, Portland, Oregon 97201, USA
Curr Opin Hematol 15:127-33. 2008..This procedure remains an option in chronic myelogenous leukemia but its use will become more sparing and selective. This review describes these trends and identifies the current role of the procedure in chronic myelogenous leukemia...
- Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industryRichard T Maziarz
International Society for Cellular Therapy, Vancouver, BC, Canada
Regen Med 6:163-6. 2011....
- Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisisJose F Leis
Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239 3098, USA
Haematologica 89:ECR30. 2004..No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis...
- Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)Jose F Leis
Oregon Health and Sciences University, Adult Bone Marrow Transplant Program, Portland, OR 97201, USA
Leuk Lymphoma 45:695-8. 2004..These results suggest that IM may not penetrate the intact blood/brain barrier and its implications are discussed...
- Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvementRichard T Maziarz
Oregon Health and Science University, Portland, OR, USA
Br J Haematol 162:648-56. 2013..CNS(+) patients can achieve excellent long-term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis...
- Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?Michael J Mauro
Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN73C, Portland, OR 97239, USA
Mayo Clin Proc 81:404-16. 2006..This review summarizes the state of transplant and nontransplant therapy for CML and discusses the decision making for patients with an aim to optimize the use of our best therapies for CML in an era of uncertainty...
- Hematopoietic stem cell transplantation for myelofibrosis: where are we now?Angela G Fleischman
Division of Hematology and Medical Oncology, Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
Curr Opin Hematol 20:130-6. 2013..A succinct yet comprehensive review of the biology of myeloproliferative neoplasms and therapeutic options with a focus on rational decision making for hematopoietic stem cell transplantation...
- Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disordersBrandon Hayes-Lattin
Adult Bone Marrow Transplant Program, Division of Hematology and Medical Oncology, Oregon Health and Science University, OHSU Cancer Institute, Portland, OR, USA
Leuk Lymphoma 45:669-80. 2004....
- Explaining family caregiver role strain following autologous blood and marrow transplantationDeborah H Eldredge
School of Nursing, Oregon Health and Science University, Portland, OR 97239, USA
J Psychosoc Oncol 24:53-74. 2006..The acuity of the recipients' illness, the life threatening nature of the treatment, and the younger age of caregivers, and recipients, may underlie these differences...
- CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host diseasePhilip R Streeter
Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
Biol Blood Marrow Transplant 10:298-309. 2004..The preferential tissue associations and distinct functional properties associated with these separable alloreactive CD4(+) CD134(+) T-cell subsets suggest that they participate differentially in clinical graft-versus-host disease...
- Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host diseaseMagdalena Kovacsovics-Bankowski
Center for Hematologic Malignancies, OHSU Cancer Institute, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
Cell Immunol 255:55-60. 2009..These data show that in vitro expanded adult stem cells can efficiently control an allo-reactive response associated with acute GVHD, that they are immuno-privileged and present strong immunosuppressive properties...
- Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphomaTarunpreet Bains
Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Leuk Lymphoma 55:583-7. 2014..There were more cases of severe mucositis but fewer episodes of bacteremia with BuMelTt. Our results suggest that BuMelTt may be a superior conditioning regimen for autoSCT in Hodgkin lymphoma...
- Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiencesLuis Espinosa-Aguilar
Department of Medicine, Oregon Health and Science University, Portland, OR, USA
Biol Blood Marrow Transplant 17:566-73. 2011..003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality...
- Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignanciesEneida R Nemecek
Oregon Health and Science University, Portland, Oregon 97239, USA
Biol Blood Marrow Transplant 17:341-50. 2011..Further trials are warranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen in more narrowly defined groups of patients...
- Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remissionMichael J Mauro
Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN73C, Portland, OR 97239, USA
Leuk Res 28:S71-3. 2004....
- Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipientsRichard T Maziarz
Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
Biol Blood Marrow Transplant 16:192-8. 2010..Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections...
- Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm populationJonathan E Brammer
Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon Electronic address
Biol Blood Marrow Transplant 21:89-96. 2015..BuFluTBI is an efficacious NMA regimen, active in both myeloid and lymphoid disease, and is ideally suited for use in patients age 65 and older or with an HCT-CI of 4 or greater. ..
- Impending challenges in the hematopoietic stem cell transplantation physician workforceJames L Gajewski
Center for Hematologic Malignancies, Oregon Health and Science University, Portland, Oregon 97239, USA
Biol Blood Marrow Transplant 15:1493-501. 2009....
- Informal caregiving in Hematopoietic Blood and Marrow Transplant patientsLiz Cooke
City of Hope, Nursing Research and Education, Duarte, CA 91010, USA
Eur J Oncol Nurs 15:500-7. 2011..Variables studied were: relationship quality, rewards of caregiving, predictability, role strain, patient function, caregiving activities, and caregiver quality of life (QOL)...
- Hematopoietic stem cell transplantation and implications for cell therapy reimbursementRichard T Maziarz
Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
Cell Stem Cell 8:609-12. 2011..We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community...
- Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantationMohamed L Sorror
Mohamed L Sorror, Rainer F Storb, Brenda M Sandmaier, Fabiana Ostronoff, H Joachim Deeg, Karen L Syrjala, Elihu Estey, David G Maloney, Frederick R Appelbaum, Paul J Martin, and Barry E Storer, Fred Hutchinson Cancer Research Center Mohamed L Sorror, Rainer F Storb, Brenda M Sandmaier, Fabiana Ostronoff, H Joachim Deeg, Karen L Syrjala, Elihu Estey, David G Maloney, Frederick R Appelbaum, and Paul J Martin, University of Washington School of Medicine Barry E Storer, University of Washington School of Public Health, Seattle, WA Smita Bhatia, City of Hope School of Medicine, Duarte, CA Richard T Maziarz, Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute and School of Medicine, Portland, OR Michael A Pulsipher, University of Utah School of Medicine and Primary Children s Medical Center, Department of Medicine
J Clin Oncol 32:3249-56. 2014..The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown...
- Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective studyEmma C Scott
Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland, OR Electronic address
Clin Lymphoma Myeloma Leuk 14:424-430.e1. 2014..Fifteen patients had cardiac involvement...
- Human multipotent adult progenitor cells transcriptionally regulate fucosyltransferase VIIGregory G Burrows
Center for Hematologic Malignancies, Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, USA Electronic address
Cytotherapy 16:566-75. 2014..Intravenous administration of MAPCs provided functional improvement in multiple pre-clinical models of injury or disease, but the mechanisms by which these outcomes were achieved remain poorly understood...
- A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphomaJohn E Levine
University of Michigan Medical Center, Ann Arbor, USA
Blood 101:2476-82. 2003..In summary, alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation, but higher TRM offsets any potential survival benefit...
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 112:3500-7. 2008..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
- Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trialDrew J Winston
Department of Medicine, UCLA Medical Center, Room 42 121 CHS, 10833 Le Conte Avenue, Los Angeles, California 90095, USA
Ann Intern Med 138:705-13. 2003..Because of concerns about fungal resistance with fluconazole and toxicity with amphotericin B, alternative prophylactic regimens have become necessary...
- Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphomaMichael B Maris
Fred Hutchinson Cancer Research Center, The University of Washington, Seattle, WA 98109 1024, USA
Blood 104:3535-42. 2004..The high response and low relapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumor responses...
- Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trialStephanie J Lee
Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 104:1559-64. 2004..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
- Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantationFrederic Baron
Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
J Clin Oncol 24:4150-7. 2006..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches...
- Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantationTibor Kovacsovics
Curr Oncol Rep 8:343-51. 2006..This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history...
- Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaSergio A Giralt
M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
Br J Haematol 137:461-7. 2007..Most patients now receive a trial of imatinib before proceeding to HCT...
- A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapyFrancis J Giles
M D Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Leuk Res 28:559-65. 2004..A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study...
- Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphomaAndrew R Rezvani
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MS D1 100, Seattle, WA 98109, USA
J Clin Oncol 26:211-7. 2008..Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting...
- HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTRRichard F Schlenk
University of Ulm, Ulm, Germany
Biol Blood Marrow Transplant 14:187-96. 2008..These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT...
- Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphomaKoen Van Besien
Lymphoma Working Committee, International Bone Marrow Transplant Registry Autologous Blood and Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
Blood 102:3521-9. 2003..We did not detect a correlation between graft-versus-host disease (GVHD) and recurrence. Finally, outcomes of transplantation for follicular lymphoma show improvement over the past decade...
- Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patientsHillard M Lazarus
Department of Medicine, The University Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
Biol Blood Marrow Transplant 11:389-98. 2005..The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials...
- In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemiaMark Bonyhadi
Xcyte Therapies, Inc, Seattle, WA 98104, USA
J Immunol 174:2366-75. 2005..Based upon these findings, a clinical trial has been initiated to test the potential therapeutic effects of T cells activated using this approach in patients with CLL...
- Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donorsUte Hegenbart
University of Leipzig, Leipzig, Germany
J Clin Oncol 24:444-53. 2006....
- Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman
Northwestern University Medical School, Chicago, Illinois, USA
Biol Blood Marrow Transplant 12:204-16. 2006..Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation...
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosingMichael B Maris
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 12:454-65. 2006..Nonmyeloablative conditioning with postgrafting cyclosporine and MMF given 3 times daily allowed 95% durable engraftment of unrelated donor G-PBMC grafts...
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioningFrederic Baron
University of Liege, Liege, Belgium
Biol Blood Marrow Transplant 13:1041-8. 2007..08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning...
- Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantationMohamed Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Cancer 112:1992-2001. 2008..Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS)...
- Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remissionDavid I Marks
Adult Blood and Marrow Transplantation BMT Unit, United Bristol Healthcare Trust, Bristol, United Kingdom
Blood 112:426-34. 2008..Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results...
- Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplantSonali M Smith
Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
Biol Blood Marrow Transplant 14:904-12. 2008..HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options...